| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Viroxime targets viral proteins 3A and 3AB, which are involved in the formation of the viral RNA replication complex, thereby inhibiting viral replication. As an antiviral agent, it inhibits viral replication. The compound is active against various RNA viruses, particularly poliovirus and rhinovirus. Its mechanism of action involves inhibiting viral replication by targeting specific viral proteins. Viroxime is an antiviral agent.
|
|---|---|
| ln Vitro |
In vitro, Viroxime shows antiviral activity against rhinovirus, enterovirus, and coxsackievirus. Enviroxime exhibits antiviral effects against EV71 with an EC₅₀ of 0.15 μM. The compound is a kinase inhibitor that targets viral proteins 3A and 3AB. Detailed in vitro data are available in the primary literature. Viroxime is a valuable tool for antiviral research.
|
| ln Vivo |
In vivo, Viroxime has antiviral activity and may be used to study coxsackievirus infection in infants. The compound has been evaluated in preclinical and clinical studies for antiviral efficacy. Further in vivo studies are needed to fully characterize its efficacy and safety profile. Viroxime is a research compound for antiviral applications.
|
| Enzyme Assay |
In vitro antiviral assays for Viroxime typically use virus-infected cell cultures (e.g., rhinovirus, enterovirus, or coxsackievirus). Cells are cultured in appropriate medium and infected with virus. The compound is dissolved in DMSO and diluted in culture medium. Infected cells are treated with Viroxime at various concentrations (0.001-100 μM) for 24-72 hours. Viral replication is assessed by plaque reduction assay, viral RNA quantification by PCR, or cytopathic effect reduction. EC₅₀ and IC₅₀ values are calculated from dose-response curves. Controls include vehicle and reference antivirals.
|
| Cell Assay |
For cell-based assays, susceptible cell lines (e.g., HeLa, Vero) are cultured in appropriate medium. Cells are seeded in multi-well plates and infected with virus. Cells are treated with Viroxime at various concentrations for 24-72 hours. Viral replication is assessed by plaque reduction assay, viral RNA quantification, or cytopathic effect reduction. Cell viability is assessed by MTT or CellTiter-Glo. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, Viroxime may be administered to animals for antiviral efficacy studies. The compound is formulated in a suitable vehicle. For viral infection models, animals are infected and treated with Viroxime at various regimens. Endpoints include viral load reduction, survival, and tissue histology. Blood samples are collected for pharmacokinetic analysis. All procedures follow institutional guidelines.
|
| ADME/Pharmacokinetics |
Viroxime (Enviroxime, MW 358.42, C₁₇H₁₈N₄O₃S) is an antiviral agent. It is a substituted benzimidazole derivative. Detailed pharmacokinetic parameters are not extensively reported in publicly available sources. The compound is typically stored at room temperature. It is for research purposes. The compound is an unseparated synthetic mixture.
|
| Toxicity/Toxicokinetics |
Toxicology data for Viroxime are limited in publicly available sources. As an antiviral agent, potential effects on host cell functions should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
Enviroxime is a substituted benzimidazole derivative active against rhinovirus and enterovirus. Enviroxime is a kinase inhibitor that targets viral proteins 3A and 3AB, which are involved in the formation of the viral RNA replication complex, thereby inhibiting viral replication.
See also: Zinviroxime (note moved to). Viroxime (Enviroxime) is a research-grade antiviral agent for studying rhinovirus, enterovirus, and coxsackievirus infections. Its primary applications include antiviral research, virology, and drug discovery. The compound is not approved for clinical use. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves inhibition of viral replication by targeting viral proteins 3A and 3AB. |
| Molecular Formula |
C17H18N4O3S
|
|---|---|
| Molecular Weight |
358.4
|
| Exact Mass |
358.11
|
| CAS # |
63198-97-0
|
| PubChem CID |
5748733
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.442
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
596
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C(C)C)(N1C(N)=NC2C=CC(/C(/C3C=CC=CC=3)=N/O)=CC1=2)(=O)=O
|
| InChi Key |
IWKXBHQELWQLHF-CAPFRKAQSA-N
|
| InChi Code |
InChI=1S/C17H18N4O3S/c1-11(2)25(23,24)21-15-10-13(8-9-14(15)19-17(21)18)16(20-22)12-6-4-3-5-7-12/h3-11,22H,1-2H3,(H2,18,19)/b20-16+
|
| Chemical Name |
(NE)-N-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7902 mL | 13.9509 mL | 27.9018 mL | |
| 5 mM | 0.5580 mL | 2.7902 mL | 5.5804 mL | |
| 10 mM | 0.2790 mL | 1.3951 mL | 2.7902 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
